Conferences

American Society of Clinical Oncology (ASCO)

American Society of Clinical Oncology (ASCO)

May 31-June 4, 2024 – Chicago, Illinois Oral Presentation: Phase 1/2 study of the TGF-β-trap-enhanced oncolytic adenovirus, AdAPT-001, plus an immune checkpoint inhibitor for patients with immune refractory cancers. Learn more

read more
Inflammasome Therapeutics Summit

Inflammasome Therapeutics Summit

November 2023; Boston, Massachusetts Oral Presentation: The Exploring the Development of RRx-001: the NLRP3 Small Molecule Inhibitor for a Variety of Inflammatory Diseases

read more
Neuroscience 2023

Neuroscience 2023

November 2023; Washington D.C. Oral Presentation: The CNS-permeable NLRP3 inhibitor RRx-001 is neuroprotective in experimental models of Parkinson’s disease

read more
SITC 2023 Spring Scientific

SITC 2023 Spring Scientific

March 2023, Denver Colorado Poster: TRIAL-IN-PROGRESS BETA-PRIME: Phase I study of AdAPT-001 as monotherapy and combined with a checkpoint inhibitor in superficially accessible, treatment-refractory solid tumors (NCT04673942) Poster: Low dose but not high dose RRx-001...

read more
3rd TGF-B for Immuno-Oncology Drug Development Summit 2023

3rd TGF-B for Immuno-Oncology Drug Development Summit 2023

January 2023, San Francisco, California Oral Presentation: Exploring the Clinical Stage TGF-β Fusion Protein Expressing Oncolytic Virus, AdAPT-001 Highlighting the safety and tolerability of TGF-β targeting OV, AdAPT-001 Using correlative studies for measuring...

read more
4th Inflammasome Therapeutics Summit 2022

4th Inflammasome Therapeutics Summit 2022

November 2022, Boston, Massachusetts Oral Presentation: RRx-001, a Small Molecule Anticancer Agent in Phase 3, Protects Against Inflammasome-Driven Diseases Evaluate strategy and execution of drug design and translational development Understanding relevant pathology...

read more
American Society for Radiation Oncology (ASTRO) 2020

American Society for Radiation Oncology (ASTRO) 2020

October 2020, Virtual Oral Presentation: Results of a Randomized, Open Label, Multicenter Trial Assessing the Safety, Dose and Schedule of RRx-001 (R001) in Reducing Severe Oral Mucositis (SOM) in Patients Receiving Chemoradiation (CRT) for Oral Cavity/oropharynx...

read more
Society for Neuro-Oncology (SNO) 2018

Society for Neuro-Oncology (SNO) 2018

November 2018, New Orleans, Louisiana Abstract: Initial clinical and advanced imaging outcomes from a multi-institutional phase 1 dose-escalation trial of RRx-001 plus whole brain radiation for patients with brain metastases

read more